Kalypsys is searching for new medicines, and has developed a zippy way to find them. Its ultra-high throughput automated epiK screening system can analyze more than one million cell-based assay wells a day and can run 24 hours a day seven days a week. With that kind of research capability, the company has developed its own bioinformatics software to enable researchers to quickly find and compare data points. Kalypsys is generous enough to market the system, under the Kalypsys Systems brand, to other pharmaceutical research facilities. Its own drug development pipeline includes compounds in early stages of development, targeting cancer, inflammatory diseases, pain, and metabolic diseases.

Isis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Isis Pharmaceuticals, Inc., through its drug discovery platform based on antisense technology, discovers and develops drugs that bind to RNA antisense technology. The company has commercialized its antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. It licenses its drugs to partners prior to late-phase development and commercialization. The company and Alnylam Pharmaceuticals jointly own Regulus Therapeutics Inc., a company focused on the discovery, development, and commercialization of microRNA therapeutics. Isis is the owner or exclusive licensee of approximately 1,600 issued patents worldwide.

Gemini Pharmaceuticals' private label products are formulated to be as effective as their name-brand twins. The company makes prescription and OTC pharmaceuticals and nutritional supplements, including acetaminophen, vitamin B-12, and herbal enhancers. Its pharmaceutical offerings include cough and cold medications, pain relievers, and sleeping aids. Its supplement product line starts with such basics as vitamins and minerals, and then includes what it calls "specialty products" such as energy boosters and weight loss supplements. Gemini Pharmaceuticals also makes pet care supplements such as joint support and allergy relief and prescription prenatal vitamins and other custom formulations.

New Brunswick Scientific Co. was founded in 1946 and is headquartered in Edison, New Jersey. As of September 24, 2007, New Brunswick Scientific Co. Inc. is a subsidiary of Eppendorf AG. New Brunswick Scientific Co., Inc. and its subsidiaries provide various research equipment and scientific instruments for the life sciences industry. It engages in the design, manufacture, and marketing of equipment that creates, maintains, measures, and controls the physical and biochemical conditions required for the growth, detection, and storage of biological cultures. The company’s products include fermentation equipment, bioreactors, biological shakers, ultra-low temperature freezers, CO2 incubators, nutrient sterilizing and dispensing equipment, tissue culture apparatus, and air samplers. Its products are used in medical, biological, chemical, and environmental research; and for the commercial development of antibiotics, proteins, hormones, enzymes, monoclonal antibodies, agricultural products, fuels, vitamins, vaccines, and other substances. The company sells its equipment to biotechnology and pharmaceutical companies; agricultural and chemical companies; other industrial customers engaged in biotechnology; and medical schools, universities, research institutes, hospitals, and private laboratories; and laboratories of federal, state, and municipal government departments and agencies. It also sells its equipment directly, as well as through scientific equipment dealers to foreign companies, institutions, and governments. The company primarily operates in the United States, Asia, and Europe.

Prometheus company markets several drugs that treat gastrointestinal disorders, such as irritable bowel syndrome and ulcerative colitis. Its Entocort, which it co-promotes with AstraZeneca, is a steroid that reduces the bowel inflammation associated with Crohn's disease. Prometheus Laboratories markets its products mainly to US gastroenterologists. It also pairs its drug offerings with a diagnostic testing service that helps doctors differentiate between various gastrointestinal diseases and prescribe the right Prometheus remedy; it runs all of its tests at its San Diego lab facility. Prometheus company plans to conduct an IPO.

SurModics, Inc. Company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. SurModics, Inc. engages in the development, manufacture, and sale of surface modification and drug delivery technologies to the healthcare industry. The company operates through four business units: Cardiovascular, Ophthalmology, SurModics Pharmaceuticals, and In Vitro Technologies. The Cardiovascular business unit supports the drug delivery and surface modification needs of cardiovascular customers by providing drug delivery polymers and coating technologies, including advanced lubricity (slippery) coatings that ease placement and maneuverability of medical devices in the body. The Ophthalmology business unit develops drug delivery systems for various drugs and other bioactive agents developed by pharmaceutical and ophthalmology companies for the treatment of serious eye diseases.The SurModics Pharmaceuticals business unit specializes in proprietary injectable microparticles and implants based on biodegradable polymers to provide sustained delivery of drugs, as well as supplies biodegradable polymers to corporate and academic customers. The In Vitro Technologies business unit specializes in in vitro diagnostic products and technologies for the biomedical research and medical diagnostic markets. Its products and technologies include protein stabilization reagents, substrates, recombinant autoimmune antigens, surface chemistry technologies for nucleic acid and protein immobilization, and diagnostic format intellectual property. The company markets its technologies and products through sales professionals, as well as sales and marketing relationships with third-parties worldwide. It has collaboration agreements with Genzyme Corporation to develop novel drug delivery solutions with an initial focus on peptide delivery.

TECHNE Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. TECHNE Corporation, along with its subsidiaries, is engaged in the development, manufacture, and sale of biotechnology products and hematology calibrators and controls. The Company’s activities are conducted, through its wholly owned subsidiaries, Research and Diagnostic Systems, Inc. (R&D Systems), and BiosPacific, Inc. (BioPacific). The Company distributes the biotechnology products in Europe, through its wholly owned United Kingdom-based subsidiary, R&D Systems Europe Ltd. (R&D Europe). The Company distributes biotechnology products in the People’s Republic of China, through its wholly owned subsidiary, R&D Systems China, Co. Ltd. (R&D China). The Company operates in three business segments: biotechnology, R&D Europe and hematology.

Perceptive Informatics understand that large clinical drug trials need more than little paper cups to dispense pills in. They also need massive information technology support to handle all of the data generated. As a subsidiary of contract research giant PAREXEL, Perceptive Informatics offers data capture and management systems for clinical trials conducted by large biotech and pharmaceutical companies. Its products are used to enroll and keep track of patients, organize trial results, and facilitate communication between participating doctors and trial organizers, as well as other services to speed the clinical-trial stage of drug development. It also manages medical imaging equipment and data for trials.

Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases and other chronic debilitating diseases, including a family of diseases known as lysosomal storage disorders (LSDs). Cardiometabolic and Renal segment develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure and endocrine and cardiovascular diseases. Biosurgery segment develops, manufactures and distributes biotherapeutics and biomaterial-based products, with a focus on products that meet medical needs in the orthopaedics and broader surgical areas. Hematologic Oncology segment develops, manufactures and distributes products for the treatment of cancer.

Bridgehead International wants to give its clients a head start. The consulting firm operates four divisions that provide a variety of services to a broad spectrum of life science companies and academic groups. Its transaction support division offers technical and commercial advice to firms developing new health care products. Healthcare education services creates medical education and communications programs for the pharmaceutical industry. The market access strategy segment helps companies evaluate competitive pricing and reimbursement models, while opportunity assessment helps firms understand the markets they are attempting to enter. The company operates across Europe, Asia, and North America.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.